EUVIMEDEUVIMED entdecken
Fallbericht

Case report of a patient with acenocoumarol resistance following therapy for infective endocarditis with rifampicin and gentamicin combination therapy

M Luszczyn, K Nowakowska, I Kolasa, B Makowski

Cardiovascular Journal of Africa · 2026

DOI: 10.5830/cvja-2025-090 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cardiovascular Journal of Africa, 2026. Verfasst von M Luszczyn und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Students Society of Interventional Cardiology, Collegium Medicum, University of Zielona Gora, Zielona Gora, Poland. Email: marialuszczyn1@gmail.c…. Hauptthemen laut MEDLINE: Rifampin, Anticoagulants, Acenocoumarol, Anti-Bacterial Agents.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vitamin K antagonists (VKAs) are essential for anticoagulation in patients with mechanical heart valves, but are affected by drug interactions, particularly with rifampicin - a potent inducer of CYP2C9 that accelerates VKA metabolism and destabilises INR levels. A 48-year-old male with multiple aortic valve replacements and infective endocarditis required rifampicin therapy post-surgery. Despite escalating doses of warfarin and acenocoumarol, therapeutic INR levels were not achieved, requiring low molecular weight heparin (LMWH) bridging. INR stabilisation occurred only after discontinuing rifampicin, with a drastic reduction in VKA dose requirements. Managing anticoagulation in patients on VKAs and rifampicin remains challenging due to rapid metabolism and INR fluctuations. Close INR monitoring, dose adjustments and alternative strategies, such as twice-daily VKA dosing or LMWH bridging, are crucial for maintaining therapeutic anticoagulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinAnticoagulantsAcenocoumarolAnti-Bacterial AgentsHeart Valve Prosthesis ImplantationGentamicinsDrug ResistanceBlood CoagulationEndocarditis, BacterialAortic ValveHumansMaleMiddle AgedTreatment OutcomeInternational Normalized RatioDrug Therapy, CombinationHeart Valve ProsthesisAnticoagulation BridgeCytochrome P-450 CYP2C9Drug InteractionsWarfarinHeparin, Low-Molecular-Weight

Stichwörter der Autor:innen

CYP2C9INR stabilisationmechanical heart valverifampicinvitamin K antagonists

Substanzen

RifampinAnticoagulantsAcenocoumarolAnti-Bacterial AgentsGentamicinsCytochrome P-450 CYP2C9WarfarinCYP2C9 protein, humanHeparin, Low-Molecular-Weight

Autor:innen und Institutionen

  • The Students Society of Interventional Cardiology, Collegium Medicum, University of Zielona Gora, Zielona Gora, Poland. Email: marialuszczyn1@gmail.com.
  • The Students Society of Interventional Cardiology, Collegium Medicum, University of Zielona Gora, Zielona Gora, Poland.
  • WSSP ZOZ Nowa Sol, Nowa Sol, Poland.
  • The Students Society of Interventional Cardiology, Collegium Medicum, University of Zielona Gora, Zielona Gora, Poland; WSSP ZOZ Nowa Sol, Nowa Sol, Poland; Department of Interventional Cardiology and Cardiac Surgery, C…

Zitieren

APA

Luszczyn, M., Nowakowska, K., Kolasa, I., & Makowski, B. (2026). Case report of a patient with acenocoumarol resistance following therapy for infective endocarditis with rifampicin and gentamicin combination therapy. Cardiovascular Journal of Africa. https://doi.org/10.5830/cvja-2025-090

Vancouver

Luszczyn M, Nowakowska K, Kolasa I, Makowski B. Case report of a patient with acenocoumarol resistance following therapy for infective endocarditis with rifampicin and gentamicin combination therapy. Cardiovascular Journal of Africa. 2026. doi:10.5830/cvja-2025-090

BibTeX
@article{Luszczyn2026,
  author = {Luszczyn, M and Nowakowska, K and Kolasa, I and Makowski, B},
  title = {Case report of a patient with acenocoumarol resistance following therapy for infective endocarditis with rifampicin and gentamicin combination therapy},
  journal = {Cardiovascular Journal of Africa},
  year = {2026},
  doi = {10.5830/cvja-2025-090}
}
Kostenlos starten →